Parathyroidectomy for adults with primary hyperparathyroidism.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
08 03 2023
08 03 2023
Historique:
pmc-release:
08
03
2024
entrez:
8
3
2023
pubmed:
9
3
2023
medline:
11
3
2023
Statut:
epublish
Résumé
Primary hyperparathyroidism (PHPT), a disorder in which the parathyroid glands produce excessive amounts of parathyroid hormone, is most common in older adults and postmenopausal women. While most people with PHPT are asymptomatic at diagnosis, symptomatic disease can lead to hypercalcaemia, osteoporosis, renal stones, cardiovascular abnormalities and reduced quality of life. Surgical removal of abnormal parathyroid tissue (parathyroidectomy) is the only established treatment for adults with symptomatic PHPT to prevent exacerbation of symptoms and to be cured of PHPT. However, the benefits and risks of parathyroidectomy compared to simple observation or medical therapy for asymptomatic and mild PHPT are not well established. To evaluate the benefits and harms of parathyroidectomy in adults with PHPT compared to simple observation or medical therapy. We searched CENTRAL, MEDLINE, LILACS, ClinicalTrials.gov and WHO ICTRP from their date of inception until 26 November 2021. We applied no language restrictions. We included randomised controlled trials (RCTs) comparing parathyroidectomy with simple observation or medical therapy for the treatment of adults with PHPT. We used standard Cochrane methods. Our primary outcomes were 1. cure of PHPT, 2. morbidity related to PHPT and 3. serious adverse events. Our secondary outcomes were 1. all-cause mortality, 2. health-related quality of life and 3. hospitalisation for hypercalcaemia, acute renal impairment or pancreatitis. We used GRADE to assess the certainty of the evidence for each outcome. We identified eight eligible RCTs that included 447 adults with (mostly asymptomatic) PHPT; 223 participants were randomised to parathyroidectomy. Follow-up duration varied from six months to 24 months. Of the 223 participants (37 men) randomised to surgery, 164 were included in the analyses, of whom 163 were cured at six to 24 months (overall cure rate 99%). Parathyroidectomy compared to observation probably results in a large increase in cure rate at six to 24 months follow-up: 163/164 participants (99.4%) in the parathyroidectomy group and 0/169 participants in the observation or medical therapy group were cured of their PHPT (8 studies, 333 participants; moderate certainty). No studies explicitly reported intervention effects on morbidities related to PHPT, such as osteoporosis, osteopenia, kidney dysfunction, urolithiasis, cognitive dysfunction or cardiovascular disease, although some studies reported surrogate outcomes for osteoporosis and cardiovascular disease. A post-hoc analysis revealed that parathyroidectomy, compared to observation or medical therapy, may have little or no effect after one to two years on bone mineral density (BMD) at the lumbar spine (mean difference (MD) 0.03 g/cm In accordance with the literature, our review findings suggest that parathyroidectomy, compared to simple observation or medical (etidronate) therapy, probably results in a large increase in cure rates of PHPT (with normalisation of serum calcium and parathyroid hormone levels to laboratory reference values). Parathyroidectomy, compared with observation, may have little or no effect on serious adverse events or hospitalisation for hypercalcaemia, and the evidence is very uncertain about the effect of parathyroidectomy on other short-term outcomes, such as BMD, all-cause mortality and quality of life. The high uncertainty of evidence limits the applicability of our findings to clinical practice; indeed, this systematic review provides no new insights with regard to treatment decisions for people with (asymptomatic) PHPT. In addition, the methodological limitations of the included studies, and the characteristics of the study populations (mainly comprising white women with asymptomatic PHPT), warrant caution when extrapolating the results to other populations with PHPT. Large-scale multi-national, multi-ethnic and long-term RCTs are needed to explore the potential short- and long-term benefits of parathyroidectomy compared to non-surgical treatment options with regard to osteoporosis or osteopenia, urolithiasis, hospitalisation for acute kidney injury, cardiovascular disease and quality of life.
Sections du résumé
BACKGROUND
Primary hyperparathyroidism (PHPT), a disorder in which the parathyroid glands produce excessive amounts of parathyroid hormone, is most common in older adults and postmenopausal women. While most people with PHPT are asymptomatic at diagnosis, symptomatic disease can lead to hypercalcaemia, osteoporosis, renal stones, cardiovascular abnormalities and reduced quality of life. Surgical removal of abnormal parathyroid tissue (parathyroidectomy) is the only established treatment for adults with symptomatic PHPT to prevent exacerbation of symptoms and to be cured of PHPT. However, the benefits and risks of parathyroidectomy compared to simple observation or medical therapy for asymptomatic and mild PHPT are not well established.
OBJECTIVES
To evaluate the benefits and harms of parathyroidectomy in adults with PHPT compared to simple observation or medical therapy.
SEARCH METHODS
We searched CENTRAL, MEDLINE, LILACS, ClinicalTrials.gov and WHO ICTRP from their date of inception until 26 November 2021. We applied no language restrictions.
SELECTION CRITERIA
We included randomised controlled trials (RCTs) comparing parathyroidectomy with simple observation or medical therapy for the treatment of adults with PHPT.
DATA COLLECTION AND ANALYSIS
We used standard Cochrane methods. Our primary outcomes were 1. cure of PHPT, 2. morbidity related to PHPT and 3. serious adverse events. Our secondary outcomes were 1. all-cause mortality, 2. health-related quality of life and 3. hospitalisation for hypercalcaemia, acute renal impairment or pancreatitis. We used GRADE to assess the certainty of the evidence for each outcome.
MAIN RESULTS
We identified eight eligible RCTs that included 447 adults with (mostly asymptomatic) PHPT; 223 participants were randomised to parathyroidectomy. Follow-up duration varied from six months to 24 months. Of the 223 participants (37 men) randomised to surgery, 164 were included in the analyses, of whom 163 were cured at six to 24 months (overall cure rate 99%). Parathyroidectomy compared to observation probably results in a large increase in cure rate at six to 24 months follow-up: 163/164 participants (99.4%) in the parathyroidectomy group and 0/169 participants in the observation or medical therapy group were cured of their PHPT (8 studies, 333 participants; moderate certainty). No studies explicitly reported intervention effects on morbidities related to PHPT, such as osteoporosis, osteopenia, kidney dysfunction, urolithiasis, cognitive dysfunction or cardiovascular disease, although some studies reported surrogate outcomes for osteoporosis and cardiovascular disease. A post-hoc analysis revealed that parathyroidectomy, compared to observation or medical therapy, may have little or no effect after one to two years on bone mineral density (BMD) at the lumbar spine (mean difference (MD) 0.03 g/cm
AUTHORS' CONCLUSIONS
In accordance with the literature, our review findings suggest that parathyroidectomy, compared to simple observation or medical (etidronate) therapy, probably results in a large increase in cure rates of PHPT (with normalisation of serum calcium and parathyroid hormone levels to laboratory reference values). Parathyroidectomy, compared with observation, may have little or no effect on serious adverse events or hospitalisation for hypercalcaemia, and the evidence is very uncertain about the effect of parathyroidectomy on other short-term outcomes, such as BMD, all-cause mortality and quality of life. The high uncertainty of evidence limits the applicability of our findings to clinical practice; indeed, this systematic review provides no new insights with regard to treatment decisions for people with (asymptomatic) PHPT. In addition, the methodological limitations of the included studies, and the characteristics of the study populations (mainly comprising white women with asymptomatic PHPT), warrant caution when extrapolating the results to other populations with PHPT. Large-scale multi-national, multi-ethnic and long-term RCTs are needed to explore the potential short- and long-term benefits of parathyroidectomy compared to non-surgical treatment options with regard to osteoporosis or osteopenia, urolithiasis, hospitalisation for acute kidney injury, cardiovascular disease and quality of life.
Identifiants
pubmed: 36883976
doi: 10.1002/14651858.CD013035.pub2
pmc: PMC9995748
doi:
Substances chimiques
Parathyroid Hormone
0
Types de publication
Systematic Review
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD013035Informations de copyright
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Références
Clin Endocrinol (Oxf). 2011 Feb;74(2):174-80
pubmed: 21044114
Eur J Endocrinol. 2015 Feb;172(2):181-7
pubmed: 25414430
Eur J Endocrinol. 2017 Jan;176(1):R39-R52
pubmed: 27601015
J Endocrinol Invest. 2016 May;39(5):567-76
pubmed: 26742935
Magn Reson Imaging Clin N Am. 2018 Feb;26(1):151-166
pubmed: 29128002
Br J Surg. 2019 Dec;106(13):1810-1818
pubmed: 31595982
J Bone Miner Res. 2017 Sep;32(9):1907-1914
pubmed: 28543873
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
JAMA Netw Open. 2022 Jun 1;5(6):e2215396
pubmed: 35657624
World J Surg. 2016 Oct;40(10):2359-77
pubmed: 27094563
J Bone Miner Res. 2022 Nov;37(11):2391-2403
pubmed: 36054638
Medicine (Baltimore). 2015 Jun;94(23):e931
pubmed: 26061318
Langenbecks Arch Surg. 2019 Dec;404(8):919-927
pubmed: 31595330
Endocr Connect. 2018 Aug 01;7(8):941-948
pubmed: 30300532
BMJ. 2000 Sep 9;321(7261):598-602
pubmed: 10977834
J Visc Surg. 2013 Dec;150(6):403-6
pubmed: 24183298
Ann Surg. 2009 Mar;249(3):469-72
pubmed: 19247036
Horm Metab Res. 2018 Mar;50(3):242-249
pubmed: 29381879
World J Surg. 2016 Mar;40(3):615-21
pubmed: 26541865
J Clin Endocrinol Metab. 2015 Apr;100(4):1309-15
pubmed: 25646791
Ann Intern Med. 2016 Jun 7;164(11):715-23
pubmed: 27043778
Psychooncology. 2013 Aug;22(8):1738-47
pubmed: 23080401
J Clin Endocrinol Metab. 2015 Dec;100(12):4399-407
pubmed: 26445115
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
JAMA Surg. 2016 Oct 1;151(10):959-968
pubmed: 27532368
J Bone Miner Res. 1999 Oct;14(10):1700-7
pubmed: 10491217
BMC Cardiovasc Disord. 2019 May 8;19(1):106
pubmed: 31068134
Surgery. 2000 Dec;128(6):1013-20;discussion 1020-1
pubmed: 11114637
Osteoporos Int. 2016 Dec;27(12):3395-3407
pubmed: 27562567
Gerontology. 2002 Mar-Apr;48(2):103-8
pubmed: 11867933
J Clin Endocrinol Metab. 2007 May;92(5):1687-92
pubmed: 17284629
Eur J Endocrinol. 2013 Jul 13;169(2):255-61
pubmed: 23744591
Langenbecks Arch Surg. 2019 Sep;404(6):681-691
pubmed: 31451913
JAMA Intern Med. 2022 Jan 1;182(1):10-18
pubmed: 34842909
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3223-3232
pubmed: 30860588
Endokrynol Pol. 2014;65(6):456-63
pubmed: 25554613
BMJ. 2003 Jan 25;326(7382):219
pubmed: 12543843
BMJ. 2017 Jul 20;358:j2998
pubmed: 28729459
BMC Med Res Methodol. 2005 Apr 20;5:13
pubmed: 15840177
JAMA Otolaryngol Head Neck Surg. 2022 May 1;148(5):448-456
pubmed: 35357400
Sci Rep. 2022 Feb 28;12(1):3333
pubmed: 35228624
J Endocrinol Invest. 2021 Jun;44(6):1127-1137
pubmed: 33074457
Ann Surg. 2010 May;251(5):832-7
pubmed: 20395857
J Endocrinol Invest. 1997 Jul-Aug;20(7):429-30
pubmed: 9309543
Surgery. 2017 Aug;162(2):429-436
pubmed: 28522130
Langenbecks Arch Surg. 2013 Jan;398(1):107-11
pubmed: 23179320
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
J Clin Epidemiol. 2020 Mar;119:126-135
pubmed: 31711912
J Clin Endocrinol Metab. 2015 Aug;100(8):3069-73
pubmed: 26079781
Surgery. 2019 Jul;166(1):50-54
pubmed: 30975497
Ann Surg. 2012 May;255(5):981-5
pubmed: 22470074
Surgery. 2002 Dec;132(6):1126-32; discussion 1132
pubmed: 12490865
Cochrane Database Syst Rev. 2007 Apr 18;(2):MR000005
pubmed: 17443628
Medicine (Baltimore). 2017 Oct;96(43):e7255
pubmed: 29068975
Br J Surg. 1996 Jun;83(6):875
pubmed: 8696772
Eur J Endocrinol. 2013 Feb 20;168(3):R45-53
pubmed: 23152439
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
J Surg Res. 2014 Jul;190(1):185-90
pubmed: 24801542
J Clin Endocrinol Metab. 2015 Apr;100(4):1359-67
pubmed: 25636048
Cochrane Database Syst Rev. 2020 Oct 21;10:CD010787
pubmed: 33085088
Int J Surg. 2015 Mar;15:55-60
pubmed: 25638734
J Clin Endocrinol Metab. 2009 Jul;94(7):2255-61
pubmed: 19351725
J Clin Endocrinol Metab. 2011 Nov;96(11):E1737-45
pubmed: 21917870
Gland Surg. 2016 Jun;5(3):352-60
pubmed: 27294044
J Clin Epidemiol. 2016 Jun;74:28-39
pubmed: 26796947
Endocr J. 2016;63(2):111-8
pubmed: 26581584
J Clin Endocrinol Metab. 2013 Aug;98(8):3213-20
pubmed: 23783096
Surgery. 2004 Dec;136(6):1281-8
pubmed: 15657588
Eur J Endocrinol. 2018 Aug;179(2):117-124
pubmed: 29875287
BMJ. 2008 Mar 15;336(7644):601-5
pubmed: 18316340
J Clin Endocrinol Metab. 2007 Aug;92(8):3114-21
pubmed: 17535997
Ann Intern Med. 2022 Jun;175(6):812-819
pubmed: 35436153
J Bone Miner Res. 2012 May;27(5):1150-8
pubmed: 22228118
Cochrane Database Syst Rev. 2023 Mar 8;3:CD013035
pubmed: 36883976
BMJ. 2010 Feb 15;340:c365
pubmed: 20156912
J Clin Endocrinol Metab. 2014 Oct;99(10):3580-94
pubmed: 25162667
Int J Surg. 2017 May;41 Suppl 1:S26-S33
pubmed: 28506410
J Clin Endocrinol Metab. 2004 Nov;89(11):5415-22
pubmed: 15531491
Osteoporos Int. 2017 Jan;28(1):1-19
pubmed: 27613721
Lancet. 2018 Jan 13;391(10116):168-178
pubmed: 28923463
J Bone Miner Res. 2021 Jan;36(1):3-11
pubmed: 33125769
Eur J Endocrinol. 2017 Dec;177(6):R297-R308
pubmed: 28864535
World J Surg. 2013 Jan;37(1):102-6
pubmed: 22968537
Surgery. 2009 Dec;146(6):1116-22
pubmed: 19879613
Br J Oral Maxillofac Surg. 2019 May;57(4):330-335
pubmed: 30930031